<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866437</url>
  </required_header>
  <id_info>
    <org_study_id>EveMS-0908</org_study_id>
    <nct_id>NCT00866437</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel</brief_title>
  <official_title>Prospective, Controlled, Single-blinded, Longitudinal, Two-arms, Clinical Study Evaluation of Efficacy/Safety of EVE-PMS Skin-Test Panel -Detecting Sensitivity to Sex Hormones in Women With Premenstrual Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EVE Medical Systems Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EVE Medical Systems Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EVE-PMS technology is intended for determination of intolerance or sensitivity to sex&#xD;
      hormones, among women suffering from severe PreMenstrual Syndrome (PMS).&#xD;
&#xD;
      The system includes skin testing panel for identification of hormones to which the patients&#xD;
      might be sensitive. Tests are applied close to the ovulation period and the skin reaction is&#xD;
      examined in 20 minutes, 48 hours and daily during the following month. Results of skin tests&#xD;
      and patient's history will determine the value of EVE-PMS Skin-Test Panel as a diagnostic&#xD;
      tool for severe PMS patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">November 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EVE-PMS Skin-Test Panel can obtain statistically significant sensitivity &amp; specificity to support the diagnosis of PMS, particularly in women with severe symptoms(i.e. breast swelling; tenderness; other PMS symptoms according to widely accepted criteria</measure>
    <time_frame>Total study duration will be approximately 2-3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal skin test related adverse events.</measure>
    <time_frame>2-3 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Premenstrual Syndrome</condition>
  <arm_group>
    <arm_group_label>Healthy Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Skin test panel</intervention_name>
    <description>Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.&#xD;
Hormones:&#xD;
Progesterone 1mmol/L&#xD;
Estradiol 1mmol/L&#xD;
Estrone 3mmol/L&#xD;
Estriol 3mmol/l&#xD;
Controls:&#xD;
Saline (NaCl) 0.9%&#xD;
Ethyl Oleate with 10% Benzyl Alcohol&#xD;
Histamine phosphate 1mg/ml (epicutaneous- prick test)</description>
    <arm_group_label>Healthy Control group</arm_group_label>
    <other_name>Progesterone</other_name>
    <other_name>Estradiol</other_name>
    <other_name>Estrone</other_name>
    <other_name>Estriol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Skin test panel</intervention_name>
    <description>Hormones:&#xD;
Progesterone 1mmol/L&#xD;
Estradiol 1 mmol/L&#xD;
Estrone 3 mmol/L&#xD;
Estriol 3mmol/l&#xD;
Controls:&#xD;
Saline (NaCl) 0.9%&#xD;
Ethyl Oleate with 10% Benzyl Alcohol&#xD;
Histamine phosphate 1mg/ml (epicutaneous- prick test)</description>
    <arm_group_label>PMS</arm_group_label>
    <other_name>Progesterone</other_name>
    <other_name>Estradiol</other_name>
    <other_name>Estrone</other_name>
    <other_name>Estriol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Person is over the age of 20 but not older than age 45.&#xD;
&#xD;
          2. Person is willing to participate as evidenced by signing the written informed consent&#xD;
             form.&#xD;
&#xD;
          3. Suffers from known dominant severe symptom of breast swelling and tenderness (level&#xD;
             7-10 according to standard scale of PMS symptoms severity)&#xD;
&#xD;
          4. Other severe symptoms of Premenstrual syndrome (based on WHO and ACOG criteria). This&#xD;
             may include one or more of PMS symptoms with level 7-10 according to standard scale of&#xD;
             PMS symptoms severity.&#xD;
&#xD;
          5. At work, school, home, or in daily routine, at least one of the PMS symptoms caused&#xD;
             reduction of productivity or inefficiency&#xD;
&#xD;
          6. At least one of the PMS symptoms caused avoidance of or less participation in hobbies&#xD;
             or social activities&#xD;
&#xD;
          7. At least one of the PMS symptoms interfere with relationships with others:&#xD;
&#xD;
             i. Timing of PMS symptom(s): during the 14 days prior to onset of menstrual flow&#xD;
             (rather than spotting) and up to 5 days during the menstrual flow.&#xD;
&#xD;
        ii. Pattern and length of PMS symptomatic period: minimum of 2 days, up to 14 days.&#xD;
&#xD;
        iii. For PMS diagnosis two out of last three consecutive menstrual cycles were monitored by&#xD;
        daily monitoring of symptoms.&#xD;
&#xD;
        iv. Timing and length of asymptomatic phase: day 6 to at least day 10 of the menstrual&#xD;
        cycle.&#xD;
&#xD;
        v. Cyclicity - presentation of the 'off-on' phenomenon: there should be a clear shift from&#xD;
        no PMS symptoms to PMS symptoms.&#xD;
&#xD;
        vi. Reliable non hormonal contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating woman&#xD;
&#xD;
          2. Oral contraceptives during last three months, including hormonal IUD (trade name&#xD;
             mirena).&#xD;
&#xD;
          3. Serious health problems.&#xD;
&#xD;
          4. Unexplained menstrual disorders.&#xD;
&#xD;
          5. Treated by hormones (estrogen and progesterone).&#xD;
&#xD;
          6. For healthy: Irregular or abnormal test results.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avner Reshef, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergy and clinical Immunology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yonit Bomstein, Dr.</last_name>
    <phone>+972-54-7889917</phone>
    <email>ybomstein@evepms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alek Itsekson, Dr.</last_name>
    <phone>+972-50-5622098</phone>
    <email>itsekson@netvision.net.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center, Tel-Hashomer</name>
      <address>
        <city>Ramat Efal</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avner Reshef, Dr</last_name>
      <phone>+972-3-5302605</phone>
      <email>Avner.Reshef@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Iris Leibovich</last_name>
      <phone>+972-3-5302605</phone>
      <email>iris.leibovich@sheba.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Avner Reshef, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>June 15, 2010</last_update_submitted>
  <last_update_submitted_qc>June 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Yonit Bomstein</name_title>
    <organization>EVE Medical Systems Ltd.</organization>
  </responsible_party>
  <keyword>PMS</keyword>
  <keyword>Hormones</keyword>
  <keyword>Skin tests</keyword>
  <keyword>Allergen Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Premenstrual Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estropipate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrone</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

